On April 2, 2018 OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, reported that strengthened its intellectual property portfolio as it filed global patent applications for 190 newly identified novel biomarkers (Press release, BioTime, APR 2, 2018, View Source;p=RssLanding&cat=news&id=2340627 [SID1234525371]). These new biomarkers may enhance OncoCyte’s lung cancer test and enable better differentiation of malignant from benign lung for improved lung cancer diagnosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OncoCyte has created a preliminary algorithm by combining some of the new biomarkers with its previously identified biomarkers. This new algorithm was cross-validated on approximately 60 clinical samples and resulted in accuracy as measured by Area Under the Curve data at least equivalent to DetermaVu’s previously reported lung cancer test results. However, the results must be confirmed in studies using a larger sample set.

OncoCyte has initiated the larger sample set study, which includes the new biomarkers along with previously identified biomarkers. This study is being carried out on three of the commercial molecular diagnostic platforms being evaluated by OncoCyte. The Company expects to complete the study during the second quarter of 2018.